Product development

Product development

Based on its proprietary findings, Regenesance currently has three programs for drug development, which target the complement pathway in order to treat immune mediated disorders and to accelerate nerve regeneration in neurological disorders.

The key mission of Regenesance is to commercialize their lead candidate Regenemab™ to treat orphan disorders with high unmet medical need, including PNH, Amyotrophic Lateral Sclerosis and Myasthenia Gravis.

product development timeline